Notably, treatment with either ASO-ELFN1-AS1 or GSK126 significantly decreased tumor volumes, and combination of either agent with oxaliplatin further prevented tumor growth, suggesting that ASO-ELFN1-AS1 and GSK126 inhibited tumor growth and restore sensitivity of oxaliplatin-resistant CRC tumors to oxaliplatin (Fig. 8c). Here, ELFN1 is linked to colorectal carcinoma.